Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 872 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: No treatment is given Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Cranberry Enhances Human Immune Function and Reduces Illness

NCT01398150
View directory record Official record
Conditions
Healthy Humans
Interventions
Beverage made to look like the cranberry beverage, Beverage made from cranberry compounds
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Sep 23, 2026, 10:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Blood Flow Restriction and Creatine Supplementation in Women

NCT05877417
View directory record Official record
Conditions
Physical Inactivity
Interventions
Creatine Monohydrate, Blood Flow Restriction, Exercise
Dietary Supplement · Device · Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 23, 2026, 10:31 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

NCT05773040
View directory record Official record
Conditions
Lymphomas, B-cell Lymphomas
Interventions
JV-213, Leukapheresis
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 23, 2026, 10:31 AM EDT
Completed Not applicable Interventional Results available

Effects of Transcranial Direct Current Stimulation (tDCS) on Language

NCT04166513
View directory record Official record
Conditions
Stroke, Aphasia
Interventions
Targeted Transcranial Direct Current Stimulation, Active Control Transcranial Direct Current Stimulation, Phonologic-Focused Speech Therapy, Semantic-Focused Speech Therapy
Device · Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 23, 2026, 10:31 AM EDT
Terminated Phase 1Phase 2 Interventional

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

NCT03933813
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Anemia, Iron Deficiency Anemia
Interventions
Iron Sucrose
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Sep 23, 2026, 10:31 AM EDT
Completed Not applicable Interventional

Comparing Acupuncture, BioModulator, and Transcutaneous Electrical Nerve Stimulation for Symptomatic Treatment of Chronic Pain.

NCT01752010
View directory record Official record
Conditions
Chronic Pain, Depression, PTSD Symptoms, Sleep
Interventions
Traditional Chinese Acupuncture, Tennant™ Biomodulator Treatment, Transcutaneous electrical nerve stimulation (TENS) Treatment
Other · Device
Lead sponsor
Samueli Institute for Information Biology
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Sep 23, 2026, 10:31 AM EDT
Suspended Phase 3 Interventional

Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet

NCT05351294
View directory record Official record
Conditions
Radiation Therapy, Metastatic Cancer
Interventions
Questionnaires, Early Radiation Oncology Involvement Alongside Standard Oncologic Care
Other · Combination Product
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Jersey City, New Jersey • New Brunswick, New Jersey • Newark, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 23, 2026, 10:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

NCT00810602
View directory record Official record
Conditions
Hematologic Malignancies, Graft vs Host Disease
Interventions
reduced intensity, related donor stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), vorinostat
Procedure · Drug
Lead sponsor
Pavan Reddy, MD
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Ann Arbor, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 23, 2026, 10:31 AM EDT
Terminated Phase 2 Interventional Results available

Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy

NCT01200602
View directory record Official record
Conditions
Anorexia, Weight Changes
Interventions
megestrol acetate, clinical observation
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 23, 2026, 10:31 AM EDT
Completed Phase 2 Interventional Results available

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

NCT01612351
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
Carboplatin, Paclitaxel, Lapatinib, Cisplatin, Ipsilateral Radiation, Bilateral Radiation, Transoral Surgery
Drug · Radiation · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 23, 2026, 10:31 AM EDT
Completed Phase 2 Interventional

Tarceva and Capecitabine for Pancreatic Cancer

NCT00125021
View directory record Official record
Conditions
Pancreatic Cancer, Neoplasm Metastasis
Interventions
Capecitabine, OSI-774
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2009 · Synced Sep 23, 2026, 10:31 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

NCT06459973
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
intravenous (IV) infusion
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
11
States / cities
Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 23, 2026, 10:31 AM EDT
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NCT07097142
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Survey Administration, Ultrahypofractionated Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
211
States / cities
Fort Smith, Arkansas • Irvine, California • La Jolla, California + 162 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 23, 2026, 10:31 AM EDT
Terminated Phase 1 Interventional

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

NCT05576077
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
TBio-4101, Pembrolizumab
Biological · Drug
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Irvine, California • Hollywood, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 23, 2026, 10:31 AM EDT
Completed Phase 3 Interventional

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis

NCT04102371
View directory record Official record
Conditions
Shock, Septic
Interventions
Lactated Ringer, Normal Saline, Plasma-lyte
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Months to 17 Years
Enrollment
9,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 23, 2026, 10:31 AM EDT
Recruiting Phase 2 Interventional

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

NCT07070466
View directory record Official record
Conditions
Stomach Cancer Stage IV, Esophagus Cancer, Stomach Cancer
Interventions
Ivonescimab, 5-Fluorouracil, Oxaliplatin, Leucovorin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Santa Monica, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 23, 2026, 10:31 AM EDT
Active, not recruiting Phase 1 Interventional

Surgical Nivolumab And Ipilimumab For Recurrent GBM

NCT04606316
View directory record Official record
Conditions
Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
Interventions
Nivolumab-Placebo, Nivolumab, Ipilimumab-Placebo, Ipilimumab, Surgery
Drug · Procedure
Lead sponsor
Patrick Wen, MD
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Stanford, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 23, 2026, 10:31 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine
Drug · Biological
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 54 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 23, 2026, 10:31 AM EDT
Terminated No phase listed Observational

An In-vitro Standardization of B Cell Elispot Assays

NCT01334281
View directory record Official record
Conditions
Transplant Sensitization, Panel Reactive Antibody, Sensitization to HLA Antigens
Interventions
Blood Draw
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 23, 2026, 10:31 AM EDT
Recruiting Phase 1 Interventional

Losartan + Sunitinib in Treatment of Osteosarcoma

NCT03900793
View directory record Official record
Conditions
Osteosarcoma
Interventions
Losartan, Sunitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 23, 2026, 10:31 AM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

NCT03500445
View directory record Official record
Conditions
Myeloma, Multiple Myeloma
Interventions
Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 23, 2026, 10:31 AM EDT
Completed Phase 2 Interventional Results available

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

NCT01839487
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
PEGPH20, Nab-paclitaxel, Gemcitabine, Dexamethasone, Enoxaparin
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
51
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 23, 2026, 10:31 AM EDT
Completed Phase 1 Interventional

A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours

NCT01281592
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumours
Interventions
LOR-253 HCl
Drug
Lead sponsor
Aptose Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Sep 23, 2026, 10:31 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin

NCT07221708
View directory record Official record
Conditions
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Interventions
Vancomycin (POC)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
65 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2027
U.S. locations
1
States / cities
Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 23, 2026, 10:31 AM EDT